top of page
Search
  • Writer's pictureFutureMeds

Streamlining the Clinical Trial Feasibility Process: Małgorzata Herrera

Understanding and predicting the best region/country-specific trial scenarios start with trial feasibility. We look into how Małgorzata Herrera (Maggie) helps clients with this important process, which can improve the chance of successful and timely study delivery.



At FutureMeds, we recognize the vital role of high-quality medical research in saving and transforming lives and driving progress in healthcare. To accelerate drug development and deliver Tomorrow's Medicines Today, we focus on transforming efficiency, delivering quality data and enhancing the patient experience. And to do that, we aim to get clinical trials underway in line with agreed timelines and protect trial delivery by finding and retaining the right candidates.


Our team's expertise and collaborative approach allow us to work closely with our CRO and Sponsor partners, identifying crucial attributes and ensuring that our trial sites are both realistic and transparent about their resource availability and access to the appropriate study population. A key figure driving our approach is Maggie, our Director of Global Feasibility and Proposals.


Maggie has played a pivotal role in streamlining FutureMeds' feasibility processes across our rapidly growing organization, fostering stronger relationships with clients, and developing feasibility strategies centered on PI expertise, insights, and patient interest.


Her efforts have led to the delivery of over 280 feasibilities to date, enabling clients to access distilled information, replace assumptions with data-driven insights, and identify region-specific and country-specific challenges, practices, and capabilities to safeguard study delivery.


“The operational insight coming from FutureMeds sites based on their experience drives our feasibility strategies. We gather recruitment and patients interest insights, uncover potential unforeseen challenges and suggest strategies that can have a positive impact on study outcomes.”

Increased transparency and reliability of FutureMeds Dedicated Research Sites


In order to maintain transparency and establish ourselves as Europe's most respected and reliable site network, FutureMeds requires country Managing Directors to collaborate with their team of experts in determining whether their sites can support specific studies. This approach enhances our ability to create proposals based on country and site-specific realities, helping clients move beyond high-level reports.


“Our approach encourages our sites to reflect on countries' standards of care, unique patients' access and identify site-specific opportunities. Through our work, our clients have the opportunity to better understand potential recruitment limitations, study design challenges from the logistic perspective and take informed next steps.”


The person behind FutureMeds feasibility drive


Maggie's passion, caring, and focus on client success have propelled her advancement in the clinical research industry for nearly two decades. Her unique drive, personality, and ability to tackle challenges set her apart in a remarkable way. She enjoys working and interacting with others, bringing functions together and finding solutions to challenges. In fact, at work, she is a high-performing engine.


“Even after 18 years of working in this field I’m still thrilled when on Monday I open the computer and start my work. It is like going on an exciting journey!”

Prior to joining FutureMeds, she held various roles in site operations, feasibility, and contractual processes at Synexus, eventually leading their global feasibility department. Following the AES acquisition of Synexus, Maggie was appointed as Director of Feasibility in 2019 and later promoted to Senior Director of Feasibility at AES.


Outside of work, Maggie stays active through walking and weightlifting, drawing inspiration from books to fuel her thirst for knowledge. With a wealth of experience and a relentless drive for excellence, Maggie is an integral part of the FutureMeds team, ensuring our feasibility processes remain agile and effective in an ever-changing healthcare landscape.



About FutureMeds


FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.


FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.


Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.



Follow us on LinkedIn


Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


Comments


Commenting has been turned off.
bottom of page